Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4053-4058

  Gershenson, David M ^a   Deavers, Michael ^a   Diaz, Sheri ^a   Tortolero Luna, Guillermo ^a   Miller, Brigitte E ^a   Bast Jr , Robert C ^a   Mills, Gordon B ^a   Silva, Elvio G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033373327     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Taylor, H. C. Malignant and semimalignant tumors of the ovary. Surg. Gynecol. Obstet., 48: 204-230, 1929.
2. Kliman, L., Rome, R. M., and Fortune, D. W. Low malignant potential tumors of the ovary: a study of 76 cases. Obstet. Gynecol., 68: 338-344, 1986.
3. Manchul, L. A., Simm, J., Levin, W., Fyles, A. W., Dembo, A. J., Pringle, J. F., Rawlings, G. A., Sturgeon, J. F., Thomas, G. M., and Simm, J. Borderline epithelial ovarian tumors: a review of 81 cases with an assessment of the impact of treatment. Int. J. Radiat. Oncol. Biol. Phys., 22: 867-874, 1992.
4. Russell, P. Borderline epithelial tumours of the ovary: a conceptual dilemma. Clin. Obstet. Gynecol., 11: 259-277, 1984.
5. Michael, H. and Roth, L. M. Invasive and noninvasive implants in ovarian serous tumors of low malignant potential. Cancer (Phila.), 57: 1240-1247, 1986.
6. McCaughey, W. T. E., Kirk, M. E., Lester, W., and Dardick, I. Peritoneal epithelial lesions associated with proliferative serous tumours of ovary. Histopathology, 8: 195-208, 1984.
7. Bell, D. A., Weinstock, M. A., and Scully, R. E. Peritoneal implants of ovarian serous borderline tumors: histologic features and prognosis. Cancer (Phila.), 62: 2212-2222, 1988.
8. De Nictolis, M., Montironi, R., Tommasoni, S., Carinelli, S., Ojeda, B., Matias-Guiu, X., and Prat, J. Serous borderline tumors of the ovary: a clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer (Phila.), 70: 152-160, 1992.
9. Seidman, J. D., and Kurman, R. J. Subclassification of serous borderline tumors of the ovary into benign and malignant types. Am. J. Surg. Pathol., 20: 1331-1345, 1996.
10. Gershenson, D. M., Silva, E. G., Levy, L., Burke, T. W., Wolf, J. K., and Tornos, C. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer (Phila.), 82: 1096-1103, 1998.
11. Gershenson, D. M., Silva, E. G., Tortolero-Luna, G., Levenback, C., Morris, M., and Tornos, C. Ovarian serous borderline tumors with noninvasive peritoneal implants. Cancer (Phila.), 83: 2157-2163, 1998.
12. Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke-Pearson, D. L., Iglehart, J. D., Bast, R. C., Jr., and Berchuck, A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51: 2979-2984, 1991.
13. Hartmann, L. C., Podratz, K. C., Keeney, G. L., Kamel, N. A., Edmonson, J. H., Grill, J. P., Su, J. Q., Katzmann, J. A., and Roche, P. C. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J. Clin. Oncol., 12: 64-69, 1994.
14. Eltabbakh, G. H., Belinson, J. L., Kennedy, A. W., Biscotti, C. V., Casey, G., Tubbs, R. R., and Blumenson, L. E. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer (Phila.), 80: 892-898, 1997.
15. Henriksen, R., Strang, P., Wilander, E., Backstrom, T., Tribukait, B., and Oberg, K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol. Oncol., 53: 301-306, 1994.
16. Levesque, M. A., Katsros, D., Yu, H., Zola, P., Sismondi, P., Giatdina, G., and Diamandis, E. P. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer (Phila.), 75: 1327-1338, 1995.
17. Klemi, P. J., Pylkkanen, L., Kiiholma, P., Kurvinen, K., and Joensuu, H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer (Phila.), 76: 1201-1208, 1995.
18. Kohler, M. F., Kerns, B. J., Humphrey, P. A., Marks, J. R., Bast, R. C., and Berchuck, A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol., 81: 643-650, 1993.
19. Allan, L. A., Campbell, M. K., Milner, B. J., Eccles, D. M., Leonard, R. C. F., Parkin, D. E., Millers, I. D., Lessells, A. M., Kitchener, H. C., and Haites, N. E. The significance of p53 mutation and overexpression in ovarian cancer prognosis. Int. J. Gynecol. Cancer, 6: 483-490, 1996.
20. Wertheim, I., Muto, M. G., Welch, W. W. R., Bell, D. A., Berkowitz, R. S., and Mok, S. C. p53 gene mutation in human borderline epithelial ovarian tumor. J. Natl. Cancer Inst., 86: 1549-1551, 1994.
21. Kupryjanczyk, J., Bell, D. A., Dimeo, D., Beauchamp, R., Thor, A. D., and Yandell, D. W. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum. Pathol., 26: 387-392, 1995.
22. Berchuck, A., Kohler, M. F., Hopkins, M. P., Humphrey, P. A., Robboy, S. J., Rodriguez, G. C., Soper, J. T., Clarke-Pearson, D. L., and Bast, R. C. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol. Oncol., 52: 232-236, 1994.
23. Kupryjanczyk, J., Bell, D. A., Yandell, D. W., Scully, R. E., and Thor, A. D. p53 expression in ovarian borderline tumors and stage I carcinomas. Am. J. Clin. Pathol., 102: 671-676, 1994.
24. Marcelli, A. R., Demopoulos, R. I., Goswami, S., and Mittal, K. R. Comparison of p53 and MIB1 expression in benign and borderline areas of ovarian serous tumors. Int. J. Gynecol. Pathol., 15: 39-44, 1996.
25. Lee, J. H., Kang, Y. S., Park, S. Y., Kim, B. G., Lee, E. D., Lee, K. H., Park, K. B., Kavanagh, J. J., and Wharton, J. T. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet. Cytogenet., 85: 43-50, 1995.
26. Koshiyama, M., Konishi, I., Mandai, M., Komatsu, T., Yamamoto, S., Nanbu, K., and Mori, T. Immunohistochemical analysis of p53 protein and 72 kDa heat shock protein (HSP72) expression in ovarian carcinomas: correlation with clinicopathology and sex steroid receptor status. Virchows Arch., 425: 603-609, 1995.
27. Klemi, P. J., Takahashi, S., Joensuu, H., Narimatsu, E., and Mori, M. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int. J. Gynecol. Pathol., 13: 228-233, 1994.
28. Kiyokawa, T. Alteration of p53 in ovarian cancer: Its occurrence and maintenance in tumor progression. Int. J. Gynecol. Pathol., 13: 311-316, 1994.
29. Eltabbakh, G. H., Belinson, J. L., Kennedy, A. W., Biscotti, C. V., Casey, G., and Tubbs, R. R. p53, and HER-2/neu overexpression in ovarian borderline tumors. Gynecol. Oncol., 65: 218-224, 1997.
30. International Federation of Gynecology and Obstetrics Cancer Committee. Staging announcement. Gynecol. Oncol., 25: 383-385, 1986.
31. Barnhill, D. R., Kurman, R. J., Brady, M. F., Omura, G. A., Yordan, E., Given, F. T., Kucera, P. R., and Roman, L. D. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J. Clin. Oncol., 13: 2752-2756, 1995.
32. Leake, J. F., Currie, J. L., Rosenshein, N. B., and Woodruff, J. D. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol. Oncol., 47: 150-158, 1992.
33. Chambers, J. T., Merino, M. J., Kohorn, E. I., and Schwartz, P. E. Borderline ovarian tumors. Am. J. Obstet. Gynecol., 159: 1088-1094, 1988.
34. Nation, J. G. and Krepart, G. V. Ovarian carcinoma of low malignant potential: staging and treatment. Am. J. Obstet. Gynecol., 154: 290-293, 1986.
35. Fritsche, M., Haessler, C., and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8: 307-318, 1993.
36. Momand, J., Zambetti, G. P., Olson, D. C., et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
37. Burks, R. T., Sherman, M. E., and Kurman, R. J. Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors. Am. J. Surg. Pathol., 20: 1319-1330, 1996.
38. Seidman, J. D., and Kurman, R. J. Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases. Am. J. Surg. Pathol., 20: 1331-1345, 1996.
39. Eichhorn, J. H., Bell, D. A., and Young, R. H. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am. J. Surg. Pathol., 23: 397-409, 1999.
40. Katabuchi, H., Tashiro, H., Cho, R. R., Kurman, R. J., and Hedrick Ellenson, L. Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53. Int. J. Gynecol. Pathol., 17: 54-60, 1998.